Two migraine prevention agents, cinnarizine and sodium valproate, were shown to be safe and effective in reducing incidence and severity of migraine within children and adolescents, according to study findings. Safety findings must be weighed alongside warnings from European regulators about the risks of valproate for girls and adolescent women who could bear children in the future.